Compare · AZN vs STTK
AZN vs STTK
Side-by-side comparison of AstraZeneca PLC (AZN) and Shattuck Labs Inc. (STTK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and STTK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $261.92B, about 453.6x STTK ($577.4M).
- Over the past year, AZN is down 10.3% and STTK is up 830.0% - STTK leads by 840.3 points.
- AZN has been more active in the news (15 items in the past 4 weeks vs 4 for STTK).
- AZN has more recent analyst coverage (25 ratings vs 13 for STTK).
- Company
- AstraZeneca PLC
- Shattuck Labs Inc.
- Price
- $168.85-0.24%
- $7.53+6.66%
- Market cap
- $261.92B
- $577.4M
- 1M return
- -5.56%
- +73.50%
- 1Y return
- -10.32%
- +829.97%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2020
- News (4w)
- 15
- 4
- Recent ratings
- 25
- 13
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Shattuck Labs Inc.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca downgraded by HSBC Securities
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 11-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest STTK
- Amendment: SEC Form SCHEDULE 13D/A filed by Shattuck Labs Inc.
- Chief Technical Officer Shukla Abhinav A. exercised 12,563 shares at a strike of $3.57 and sold $2,874 worth of shares (410 units at $7.01) as part of a pre-agreed trading plan, increasing direct ownership by 14% to 98,533 units (SEC Form 4) to satisfy withholding obligation
- Chief Technical Officer Shukla Abhinav A. exercised 23,465 shares at a strike of $3.57 and sold $166,131 worth of shares (23,465 units at $7.08) as part of a pre-agreed trading plan (SEC Form 4) (for tax liability)
- Chief Medical Officer Pandite Arundathy N. sold $210,300 worth of shares (30,000 units at $7.01) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 136,219 units (SEC Form 4)
- SEC Form 4 filed by Director Ashiya Mona
- SEC Form 4 filed by Director Orbimed Advisors Llc
- Amendment: SEC Form SCHEDULE 13D/A filed by Shattuck Labs Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Shattuck Labs Inc.
- Director Siegall Clay B bought $250,000 worth of shares (62,500 units at $4.00), increasing direct ownership by 24% to 318,608 units (SEC Form 4)
- SEC Form 8-K filed by Shattuck Labs Inc.